Alnylam Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $313.7M | $-278.2M | $-440.2M | $-1.13B | $-852.8M | $-858.3M | $-886.1M | $-761.5M |
| Depreciation & Amortization | $55.7M | $56.7M | $54.1M | $44.5M | $47.6M | $34.8M | $17.2M | $15.2M |
| Depreciation | $54.8M | $55.1M | $51.6M | $39.1M | $36.8M | $30.2M | $16.6M | $12.8M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $348.2M | $272.1M | $221.7M | $230.6M | $165.7M | $139.9M | $174.8M | $157.8M |
| Net Cash from Operating Activities | $524.1M | $-8.3M | $104.2M | $-541.3M | $-641.7M | $-615.0M | $-278.4M | $-562.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $58.7M | $34.3M | $62.2M | $72.1M | $76.4M | $70.4M | $140.2M | $126.9M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $436.3M | $-116.8M | $-336.4M | $169.4M | $-273.3M | $-435.5M | $-417.7M | $272.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-305.2M | $294.2M | $172.1M | $425.8M | $1.25B | $995.0M | $823.2M | $65.5M |
| Net Change in Cash | $690.2M | $153.8M | $-53.7M | $46.4M | $323.1M | $-50.6M | $127.0M | $-224.2M |
| Free Cash Flow | $465.4M | $-42.6M | $41.9M | $-613.3M | $-718.1M | $-685.3M | $-418.6M | $-689.5M |